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The development of a vaccine against human cytomegalovirus (CMV) has been a subject 
of long-term medical interest. The research during recent years identified CMV as an 
attractive vaccine vector against infectious diseases and tumors. The immune response 
to CMV persists over a lifetime and its unique feature is the inflationary T cell response to 
certain viral epitopes. CMV encodes numerous genes involved in immunoevasion, which 
are non-essential for virus growth in vitro. The deletion of those genes results in virus 
attenuation in vivo, which enables us to dramatically manipulate its virulence and the 
immune response. We have previously shown that the murine CMV (MCMV) expressing 
RAE-1γ, one of the cellular ligands for the NKG2D receptor, is highly attenuated in vivo 
but retains the ability to induce a strong CD8+ T cell response. Here, we demonstrate 
that recombinant MCMV expressing high affinity NKG2D ligand murine UL16 binding 
protein-like transcript (MULT-1) (MULT-1MCMV) inserted in the place of its viral inhibitor 
is dramatically attenuated in vivo in a NK cell-dependent manner, both in immunocom-
petent adult mice and in immunologically immature newborns. MULT-1MCMV was 
more attenuated than the recombinant virus expressing RAE-1γ. Despite the drastic 
sensitivity to innate immune control, MULT-1MCMV induced an efficient CD8+ T  cell 
response to viral and vectored antigens. By using in vitro assay, we showed that similar 
to RAE-1γMCMV, MULT-1 expressing virus provided strong priming of CD8+ T  cells. 
Moreover, MULT-1MCMV was able to induce anti-viral antibodies, which after passing 
the transplacental barrier protect offspring of immunized mothers from challenge infec-
tion. Altogether, this study further supports the concept that CMV expressing NKG2D 
ligand possesses excellent characteristics to serve as a vaccine or vaccine vector.
Keywords: murine cMV, cytomegalovirus, vaccine, nKg2D, murine Ul16 binding protein-like transcript 1, nK cells, 
cD8+ T cells
inTrODUcTiOn
Human cytomegalovirus (HCMV) is a member of herpesvirus family with high seroprevalence rate 
worldwide (1). After acute infection, cytomegaloviruses (CMVs) establish life-long latency from 
which periodic reactivations can occur. In immunocompetent individuals CMV is usually asymp-
tomatic, whereas infection in immunocompromised or immunologically immature individuals can 
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cause a severe morbidity (2, 3). In healthy individuals, CMV is 
controlled by the combined effort of innate and adaptive immu-
nity. While NK cell control is critical during the first days of infec-
tion, long-term virus control is maintained predominantly by 
T cells and antibodies (4–6). Despite several decades of intensive 
work, no HCMV vaccine is still approved (7).
NKG2D is an activating immune receptor expressed on 
NK cells, activated and antigen-experienced T cells, and a pro-
portion of NKT and γδ T cells (8). When expressed on NK cells, 
NKG2D acts as a strong activating receptor, while its engagement 
on T cells provides co-stimulation (9, 10). Ligands for NKG2D 
are structurally similar to MHC class I molecules and normally 
expressed at very low levels. However, upon cellular stress caused 
by infection or cell transformation, their expression increases 
leading to NKG2D engagement and activation of immune cells 
(11, 12). In humans, NKG2D ligands include highly polymorphic 
MHC-I-related proteins MICA and MICB and UL16-binding 
proteins (ULBPs) (13). In mice, ligands for NKG2D receptor 
belong to the family of retinoic acid inducible early transcripts 1 
(RAE-1), histocompatibility 60 (H60), and murine UL16 binding 
protein-like transcript (MULT-1). Although binding to the same 
receptor, NKG2D ligands differ in their regulation and affinity for 
the receptor. It is still not fully understood which consequence 
has the engagement of different NKG2D ligands on the functional 
outcome of NK and T cell response.
The best evidence that NKG2D engagement plays an important 
role in immunosurveillance of CMV is the fact that CMV pos-
sesses several immunoevasion genes, which prevent the surface 
expression of NKG2D ligands (14, 15). In MCMV, the majority 
of these genes belong to the m145 family of immunoevasins 
which includes m145, m152, and m155 gene products targeting 
MULT-1, RAE-1, and H60, respectively (16–18). In addition, 
viral FcRγ receptor encoded by the m138 gene has been shown 
to downmodulate the expression of H60, MULT-1, and RAE-1ε 
ligands (19, 20).
Murine CMV mutants lacking proteins involved in the 
regulation of NKG2D ligands are attenuated in vivo by NK cells. 
We exploited this knowledge of NKG2D immunoevasion to 
develop novel CMV-based vaccine vectors. Recombinant MCMV 
expressing NKG2D ligand RAE-1γ, inserted in a place of its viral 
regulator m152 is severely attenuated in  vivo, but nevertheless 
induces strong antigen-specific CD8+ T cell response to CMV and 
vectored antigens, providing long-term protection against bacte-
rial infection and tumors (21–23). Likewise, HCMV expressing 
ULBP2 in place of its viral regulator is susceptible to control by 
NK cells, but preserved the ability to stimulate HCMV-specific 
T cells (24).
In this work, we constructed new MCMV-based vaccine 
vector expressing NKG2D ligand MULT-1 in place of its viral 
regulator m145. Based on our previous results on RAE-1γMCMV, 
we hypothesized that MULT-1MCMV would also be efficiently 
controlled while retaining ability to induce potent CD8+ T cell 
response. Indeed, MULT-1MCMV was dramatically attenuated 
in  vivo by NK  cells and virus was cleared more rapidly than 
RAE-1γMCMV. Nevertheless, MULT-1MCMV induced a strong 
CD8+ T cell response and anti-viral antibodies. This study further 
supports our previous results showing that recombinant CMVs 
expressing NKG2D ligands can be utilized as efficient vaccines 
and vaccine vectors.
MaTerials anD MeThODs
construction of recombinant McMV 
Viruses
Wild-type (WT) MCMV refers to a bacterial artificial chromo-
some (BAC)-derived mouse cytomegalovirus, MW97.01, previ-
ously shown to be biologically equivalent to the MCMV Smith 
strain (VR-1399). Construction of WT MCMV, Δm152MCMV, 
and RAE-1γMCMV expressing SIINFEKL was described previ-
ously (21, 22, 25). MULT-1MCMV, MULT-1MCMV expressing 
SIINFEKL and Δm145MCMV expressing SIINFEKL were 
constructed according to published procedure (26). Briefly, for 
construction of MULT-1MCMV an ORF encoding FLAG-tagged 
MULT-1 was first cloned into a plasmid containing kanamycin 
resistance gene (KanR), I-SceI restriction site, and HCMV imme-
diate early promoter (hMIEP) upstream of the cloning site (kind 
gift from Martin Messerle). The MULT-1 expression cassette con-
taining KanR was PCR amplified using primers 5′-GGGTTAAA
ACCGCACACAGATGTAGGGGCAGACTCT GAGGACCGGT
GTTTCAACTCCGCGGTTGACATTGATTATTGACT-3′ and 
5′-GTGAGGGGATTATGTCCTGTTTATTGTC-TCACGACA
GACATACAGAGATTCGGACAGTCATCATGGGATCCCG
TCGATGT-3′, which contained 60 nucleotides at their 5′ ends 
homologous to the intended integration site in the BAC-cloned 
MCMV genome, thereby replacing the m145 ORF following the 
homologous recombination. To swap the sequence of Dd restricted 
antigenic m164167–175 peptide AGPPRYSRI with Kb restricted 
peptide SIINFEKL, linear DNA fragment was generated using 
KanR as a template and primers 5′-GCCGTTCGGAAAGG
ACTACTGTCGGACGTGGGGCG CTGACAGTATAATCA
ACTTTGAAAAACTGAGGATGACGACGATAAGT-3′ and 
5′-AAGGTCTCCTCGCCCGCTGCCACGATGG-CCTGGTTG
TTGACGGCCCAGAACAGTTTTTCAAAGTTGATTATACT
GTCAGCGCCCCACCAACCAATTAACCAATTC-3′ for PCR 
amplification. Δm145MCMV expressing SIINFEKL was cons-
tructed by deletion of MULT-1 from MULT-1MCMV expre ssing 
SIINFEKL according to the same procedure using 5′-GGGTTAAA 
ACCGCACACAGATGTAGG-GGCAGACTCTGAGGACCG
GTGTTTCAACTCCGCGAGGATGACGACGATAAGTAG-3′ 
and 5′-GATTATGTCCTGTTTATTGTCTCACGACAGACATA 
CAGAGATTCGGACAGCGCGGAG-TTGAAACACCGG 
TCCTCAGAGTCTGCCCCTACACAACCAATT AACCAA 
TTCTG-3′ primers resulting in m145 deletion.
cells and Virus Propagation
BALB/c mouse embryonic fibroblasts (MEF) were grown accord-
ing to published procedure (27). MEF and SVEC4-10 cells were 
infected with 1.5 or 3 PFU/cell, respectively. Viruses were propa-
gated on MEF and concentrated by sucrose gradient ultracen-
trifugation (28). To assess virus replication in vitro by multi-step 
growth kinetics assay, MEF were infected with 0.1  PFU/cell of 
WT MCMV, RAE-1γMCMV, and MULT-1MCMV. Supernatants 
were harvested at indicated times after infection and virus titers 
were determined by plaque assay (28).
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Mice and infection
C57BL/6, congenic C57BL/6 (Ly5.1/CD45.1+), NKG2D−/− (29), 
BALB/c, TCR transgenic mice specific for M38 (Maxi) (30), and 
SIINFEKL (OT-1) (31) were bred under specific pathogen-free 
conditions at the Faculty of Medicine, University of Rijeka. 
All experiments performed in this study were approved by the 
Animal Welfare Committee of the University of Rijeka. Unless 
otherwise noted, gender matched mice at age of 8–16 weeks were 
infected with 2 ×  105  PFU of tissue culture derived recombi-
nant MCMV either in the footpad (f.p.) or intravenously (i.v.). 
Newborn BALB/c mice were infected intraperitoneally (i.p.) with 
500 PFU of indicated viruses 6 h after birth. Newborn C57BL/6 
mice were infected i.p. with 200 or 500 PFU of indicated viruses 
24  h post-partum. In vivo blocking of NKG2D and depletion 
of NK cells was performed by i.p. injection of mouse α-mouse 
NKG2D blocking antibody (generated by Center for Proteomics, 
University of Rijeka, Faculty of Medicine, clone NKG2D.03) or 
mouse α-mouse NK1.1 (clone PK136) (32) and rabbit α-asialo 
GM1 antiserum (αAGM1) (Wako Chemicals), respectively. Viral 
titers from organs were determined by a plaque assay (28).
adoptive Transfer
For adoptive transfer experiments C57BL/6 or C57BL/6 CD45.1+ 
mice were immunized f.p. with 2 × 105 PFU of indicated viruses. 
After 6 weeks, total CD8+ T cells were enriched from splenocytes 
using CD8a+ T Cell Isolation Kit (Miltenyi) and sorted on BD 
FACSAriaII. Adult C57BL/6 recipients were administrated i.p. 
with 250 µg of depleting NK1.1 antibody (PK136) 1 day prior to 
sublethal irradiation with 7 Gy. Next day, mice were i.v. injected 
with 106 sorted CD8+ T cells. Newborn C57BL/6 mice were i.p. 
injected with 105 sorted CD8+ T cells 1 day prior to infection.
In Vitro stimulation of cD8+ T cells
Bone marrow cells isolated from both femurs and tibias of C57BL/6 
mice were differentiated into bone marrow-derived dendritic 
cells (BMDCs) in the presence of J558 supernatant for 6 days (33). 
BMDCs were infected with 2 PFU/cell of indicated viruses. After 
24 h of infection corresponding amount of either Maxi or OT-1 
splenocytes was added at different T:E (BMDCs:CD8+) ratios, 
together with Brefeldin A (Sigma). After 6  h of co-incubation, 
intracellular staining for IFN-γ production was performed.
Flow cytometry and immune assays
For staining of cell surface expression of NKG2D ligands, mouse 
NKG2D protein fused with human Fc fragment was used, fol-
lowed by conjugated donkey α-human IgG Fc secondary antibody 
(Jackson Immunoresearch). Alternatively, mouse α-mouse RAE-
1γ (generated by Center for Proteomics, University of Rijeka, 
Faculty of Medicine, clone RAE-1γ0.01) or rat α-mouse MULT-1 
(clone 1D6) (18) was used, followed by fluorochrome conjugated 
goat α-mouse IgG (BD Pharmingen) and goat α-rat IgG F(ab′)2 
(Santa Cruz) secondary antibody, respectively. As isotype con-
trol irrelevant protein fused with human Fc was used (human 
PVR-Fc) or antibodies of same isotype originating from the 
same host, respectively. Splenocytes from immunized C57BL/6 
mice were either immediately stained with fluorescently labeled 
antibodies for assessment of CD8+ T cell phenotype or incubated 
in the presence of 5 μg/ml H-2b restricted custom synthesized 
peptides of M45 (985HGIRNASFI993), M38 (316SSPPMFRV323), 
and ovalbumin (257SIINFEKL264) (JPT Peptide Technologies) in 
presence of Brefeldin A (Sigma) for cytokine production. After 
4  h of stimulation, cells were stained for viability, expression 
of surface markers, and intracellular cytokines. Reagents used 
in flow cytometry analysis were purchased from eBioscience/
Thermo Fischer Scientific and included: Fixable Viability Dye, 
αCD8 (clone 53-6.7), αCD44 (clone IM7), αCD62L (clone MEL-
14), αCD127 (clone SB/199), αIFNy (clone XMG1.2), and αTNF 
(clone MP6-XT22) antibodies. Following reagents were obtained 
through NIH Tetramer Core Facility: H-2K(b) MCMV M38 
(316SSPPMFRV323), H-2L(d) MCMV IE1 (168YPHFMPTNL176), 
and H-2D(d) MCMV m164 (257AGPPRYSRI265). SIINFEKL-
specific multimer H-2Kb/SIINFEKL MHC multimer was kindly 
provided by Dirk Busch (Munich). Samples were analyzed on BD 
FACSAriaII using FACSDiva and FlowJo (Tree Star, Inc.).
elisa
For detection of MCMV-specific total IgG in immune sera, high 
binding ELISA plates were coated with lysate of Δm138MCMV 
infected MEF as previously described (34). Shortly, sera of mice 
were incubated overnight at +4°C, followed by extensive wash-
ing and detection with peroxidase conjugated goat α-mouse IgG 
(H + L) (Jackson Immunoresearch).
statistical analysis
Statistical significance was calculated by unpaired two-tailed 
Student’s t-test or Mann–Whitney U test for statistical analyses of 
the virus titers. Differences in MCMV-specific antibody titers in 
sera of immune animals were analyzed using two-way-ANOVA 
and Bonferroni post hoc test. P values less than 0.05 were con-
sidered significant. Only statistically significant differences are 
indicated in figures. All data were analyzed using GraphPad 
Prism 5 software.
resUlTs
construction and In Vitro characterization 
of recombinant McMV expressing  
MUlT-1
MULT-1MCMV was constructed by replacing the m145 gene, 
encoding a viral inhibitor of MULT-1, with the gene encoding 
MULT-1 under the control of hMIEP (Figure  1A). The con-
struction of RAE-1γMCMV was described previously (21, 22). 
To study CD8+ T  cell response induced by these recombinant 
viruses against well characterized CD8+ T cell epitope, all viruses 
used in this study expressed the immunodominant Kb epitope 
SIINFEKL in place of Dd restricted antigenic m164 epitope 
(Figure 1A). MCMV expressing only SIINFEKL was used as a 
control (hereby referred as WT MCMV) (25). MULT-1MCMV 
replication in  vitro was comparable to WT MCMV and RAE-
1γMCMV (Figure 1B). To measure the expression of NKG2D 
ligands on the surface of infected cells, MEF were infected with 
WT MCMV, Δm152MCMV, RAE-1γMCMV, Δm145MCMV, 
FigUre 1 | Recombinant viruses used in this study. (a) Recombinant murine CMV (MCMV) was made by insertion of genes for NKG2D ligands, RAE-1γ, and 
murine UL16 binding protein-like transcript-1 (MULT-1) in place of m152 and m145, respectively. OVA-derived Kb restricted CD8+ T cell epitope SIINFEKL was 
swapped with Dd restricted viral CD8+ T cell epitope of m164 167AGPPRYSRI175. (B) Multi-step growth kinetics assay on mouse embryonic fibroblasts (MEF) 
comparing wild-type (WT) MCMV, RAE-1γMCMV, and MULT-1MCMV is shown. (c,D) MEFs were infected with 1.5 PFU/cell of indicated viruses and expression of 
NKG2D ligands was evaluated 24 h after infection by staining either with (c) mouse NKG2D-Fc fusion protein (black line) or (D) αRAE-1γ (upper row, black line), 
αMULT-1 (lower row, black line), and appropriate isotype controls (gray). (e) SVEC4-10 cells were infected with 3 PFU/cell of WT MCMV, Δm145MCMV, and 
MULT-1MCMV for 16 h. Surface expression of MULT-1 was detected with αMULT-1 (black line) or isotype control (gray).
4
Hiršl et al. Immunobiology of MCMV Expressing MULT-1
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 991
5Hiršl et al. Immunobiology of MCMV Expressing MULT-1
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 991
and MULT-1MCMV for 24  h. To assess the expression of 
exogenous NKG2D ligands as well as endogenous NKG2D 
ligands affected by the deletion of viral evasins, staining was 
performed using mouse NKG2D-Fc fusion protein (Figure 1C). 
Expression of inserted NKG2D ligands on the surface of RAE-
1γMCMV or MULT-1MCMV infected cells was confirmed by 
staining with specific antibodies against RAE-1γ and MULT-1, 
respectively (Figure 1D). As previously published, WT MCMV 
downregulated NKG2D ligands from the cell surface and dele-
tion of m152 substantially restored RAE-1 surface expression 
(35). However, infection of MEF with MULT-1MCMV resulted 
in high surface expression of MULT-1. Furthermore, both 
RAE-1γMCMV and MULT-1MCMV infected cells showed 
similar binding of NKG2D-Fc (Figure 1C). Since MEF consti-
tutively express very low level of MULT-1, the effect of m145 
deletion on the expression of this ligand was hardly detect-
able. However, the impact of m145 on the surface expression 
of MULT-1 was detectable after infecting SVEC4-10 cells that 
constitutively express MULT-1 (Figure 1E) (18, 19). Altogether, 
these data demonstrate that cells infected with MULT-1MCMV 
express high levels of MULT-1 on their surface and its expres-
sion was not abrogated by function of other viral regulator 
of MULT-1.
MUlT-1McMV is strongly attenuated in 
adult and neonatal Mice
To determine how expression of high affinity NKG2D ligand 
MULT-1 affects viral control in vivo, BALB/c mice were infected 
with WT MCMV, RAE-1γMCMV, and MULT-1MCMV i.v. and 
viral titers were analyzed at different times after infection. By the 
day 4 after infection both RAE-1γMCMV and MULT-1MCMV 
were heavily attenuated in spleen, lungs, and liver (Figures 2A,C). 
Moreover, in liver MULT-1MCMV was even more attenuated as 
compared to RAE-1γMCMV (Figure 2C). Both RAE-1γMCMV 
and MULT-1MCMV were also attenuated in lungs at day 14 post 
infection compared to WT MCMV and were completely unde-
tectable in salivary glands (Figure 2A). As shown previously (18), 
Δm145MCMV was attenuated as compared to WT MCMV, but 
attenuation of MULT-1MCMV was even stronger (Figure S1A in 
Supplementary Material).
We have previously shown that RAE-1γMCMV was attenuated 
in immunologically immature newborns (21). Here, we show that 
MULT-1MCMV was severely attenuated in newborn mice as well 
(Figure 2B). Surprisingly, MULT-1MCMV was controlled more 
rapidly than RAE-1γMCMV in infected newborns, with virus 
undetectable at the day 8 after infection.
To identify the immune mechanism responsible for the effi-
cient control of MULT-1MCMV, groups of infected BALB/c mice 
were treated either with αAGM1 to deplete NK cells or NKG2D 
blocking antibody. Blocking of NKG2D receptor abolished the 
differences between mutant viruses and WT MCMV suggesting 
that early attenuation of recombinant viruses expressing NKG2D 
ligands is exclusively NKG2D-dependent. Depletion of NK cells 
by αAGM1 also resulted in the abrogation of differences in viral 
titer between the groups (Figure  2C). It has been well estab-
lished that NK cells in MCMV resistant C57BL/6 mice control 
virus via a direct recognition of viral m157 protein by Ly49H 
activating receptor (36). Notably, viruses expressing NKG2D 
ligands were more sensitive to NK cell-dependent control even 
in C57BL/6 mice but this phenotype was lost in NKG2D−/− mice 
(Figure 2D).
MUlT-1McMV induces a strong and 
Functional antigen-specific cD8+  
T cell response
We have already shown that MCMV expressing NKG2D ligand 
RAE-1γ induces a strong CD8+ T  cell response despite its 
attenuation in vivo (21, 22). To examine CD8+ T cell response 
after MULT-1MCMV infection, C57BL/6 mice were infected 
into footpad with WT MCMV, RAE-1γMCMV, and MULT-
1MCMV. Antigen-specific CD8+ T cell response was evaluated 
in the early (7 days) and late (2 months) phase of infection by 
measuring IFN-γ and TNF-α production after stimulation with 
non-inflationary peptide M45, inflationary peptide M38, as 
well as OVA-derived peptide SIINFEKL (Figure 3A; Figure S2 
in Supplementary Material). At both time points after infection 
the frequencies and absolute numbers of virus-specific CD8+ 
T cells were comparable or higher in MULT-1MCMV immu-
nized animals compared to WT MCMV. While virus-specific 
CD8+ T  cell response was similar in RAE-1γMCMV and 
MULT-1MCMV, RAE-1γMCMV induced more CD8+ T  cells 
specific for the vectored epitope SIINFEKL. Furthermore, 
RAE-1γMCMV induced more effector memory SIINFEKL-
specific CD8+ T cells than MULT-1MCMV, while frequency of 
M38-specific memory subsets was comparable between viruses 
(Figure S3 in Supplementary Material). Of note, although 
MULT-1MCMV was attenuated compared to Δm145MCMV, 
both viruses indu ced similar CD8+ T cell response (Figure S1B 
in Supplementary Material).
To circumvent the impact of a different antigenic load, we 
performed an in  vitro stimulation of CD8+ T  cells. BMDCs 
were infected with WT MCMV, RAE-1γMCMV, and MULT-
1MCMV and co-incubated with splenocytes isolated from naive 
TCR transgenic mice possessing CD8+ T  cells specific for the 
M38 epitope (Maxi) or SIINFEKL (OT-1) (Figure 3B). MULT-
1MCMV infected BMDCs stimulated a higher proportion of 
Maxi CD8+ T cells to produce IFN-γ compared to WT MCMV 
and equal to RAE-1γMCMV. In accordance with data presented 
in Figure 3A, RAE-1γMCMV infected BMDCs provided supe-
rior stimulation of OT-1 CD8+ T cells. However, MULT-1MCMV 
infected BMDCs stimulated OT-1 CD8+ T cells better than WT 
MCMV. Altogether, MULT-1MCMV induced a robust antigen-
specific CD8+ T cells response to both viral and vectored epitopes 
in both acute and latent phase of infection.
Long-term CD8+ T  cell memory formation is critical for 
protection upon challenge infection later in life. To assess 
the protective capacity of virus-specific CD8+ T cells induced 
by MULT-1MCMV, adoptive transfer experiments were 
performed. CD8+ T cells were sorted from C57BL/6 CD45.1+ 
donor mice latently infected with WT MCMV, RAE-1γMCMV, 
and MULT-1MCMV and adoptively transferred into NK 
depleted and irradiated C57BL/6 CD45.2+ recipients infected 
FigUre 2 | Recombinant murine CMV (MCMV) expressing MULT-1 is controlled by NK cells in NKG2D-dependent manner. (a) BALB/c mice were infected 
intravenously (i.v.) with 2 × 105 PFU of wild-type (WT) MCMV, RAE-1γMCMV, and MULT-1MCMV. On day 4 and 14 after infection viral titer was determined in organs 
by plaque assay. (B) Newborn C57BL/6 mice were infected with 200 PFU of WT MCMV, RAE-1γMCMV, and MULT-1MCMV intraperitoneally (i.p.) 24 h after birth. 
Viral titer was determined in organs by plaque assay on day 8 and 14 after infection. (c) BALB/c mice received 20 µl of αAGM1 or 250 µg of NKG2D blocking 
antibody i.p. 2 h before infection and additional dose of NKG2D blocking antibody on day 2 after i.v. infection with 2 × 105 PFU of WT MCMV, RAE-1γMCMV, and 
MULT-1MCMV. Viral titer was determined in organs by plaque assay on day 4 after infection. (D) C57BL/6 and NKG2D−/− mice were i.v. infected with 5 × 105 PFU of 
WT MCMV, RAE-1γMCMV, and MULT-1MCMV. On day 4 after infection viral titer was determined in organs by plaque assay. Each circle represents an individual 
animal and lines represent medians. Data were analyzed using Mann–Whitney U test. Asterisks denote significant values: *P < 0.05; **P < 0.01. Abbreviation: DL, 
detection limit.
6
Hiršl et al. Immunobiology of MCMV Expressing MULT-1
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 991
with WT MCMV (Figure  4A). CD8+ T  cells from MULT-
1MCMV immunized donors controlled the infection in lungs 
and liver of challenged recipients more efficiently than non-
immune CD8+ T  cells and equally efficient as CD8+ T  cells 
obtained from WT MCMV and RAE-1γMCMV immuniza-
tion. By using a similar approach, we evaluated the protective 
capacity of MULT-1MCMV immunization by transferring 
immune CD8+ T  cells into newborn mice infected with WT 
MCMV (Figure 4B). CD8+ T cells derived from WT MCMV, 
RAE-1γMCMV, and MULT-1MCMV infected mice provided 
a similar level of protection in this model as well. Altogether, 
our results demonstrated that antigen-specific CD8+ T  cells 
induced by highly attenuated MULT-1MCMV are functional 
and protective against MCMV infection.
immunization of Female Mice With MUlT-
1McMV Provides antibody Mediated 
Protection to Their Offspring
Induction of protective antibody response is a favorable feature of 
any vaccine. To determine whether MULT-1MCMV can induce 
MCMV-specific antibodies in immunized mothers which could 
protect their offspring from MCMV disease, BALB/c females 
were infected with WT MCMV, RAE-1γMCMV, and MULT-
1MCMV 2 weeks prior mating (Figure 5A). Analysis of immune 
sera showed that MULT-1MCMV immunized mothers, as well 
as their offspring, had a substantial level of MCMV-specific anti-
bodies (Figure 5B). There was no difference in levels of anti-viral 
antibodies between MULT-1MCMV compared to WT MCMV. 
FigUre 3 | Attenuated MULT-1MCMV induces strong antigen-specific CD8+ T cell response and efficiently stimulates CD8+ T cells in vitro. C57BL/6 mice were 
infected footpad with 2 × 105 PFU of wild-type (WT) MCMV, RAE-1γMCMV, and MULT-1MCMV. (a) At different times after infection CD8+ T cells from spleen were 
analyzed after peptide stimulation for cytokine production (n = 5). (B) C57BL/6 bone marrow-derived dendritic cells (BMDCs) were infected with 2 PFU/cell of WT 
MCMV, RAE-1γMCMV, or MULT-1MCMV. After 24 h, infected BMDCs were co-incubated with splenocytes from Maxi or OT-1 mice for 6 h and IFN-γ production was 
measured by flow cytometry. Representative data from two to five independent experiments are shown. Data are presented as mean ± SEM and were analyzed 
using Student’s t-test. Asterisks denote significant values: *P < 0.05; **P < 0.01; ***P < 0.001.
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As shown previously, slightly lower antibody titer was observed in 
mice immunized with RAE-1γMCMV (21). Moreover, newborns 
from MULT-1MCMV immunized mothers were completely pro-
tected upon infection with WT MCMV, as well as newborns from 
WT MCMV and RAE-1γMCMV immunized dams (Figure 5C). 
Altogether, these data show that despite a strong attenuation, 
MULT-1MCMV immunization of mothers induces a strong 
production of anti-viral antibodies, which can pass the placenta 
and protect their offspring from MCMV disease.
DiscUssiOn
After resolution of primary CMV infection, CD8+ T cells spe-
cific for certain immunodominant epitopes are not maintained 
as a low abundant memory population, but rather gradually 
increase in frequency acquiring an effector-like phenotype, 
a phenomenon known as “memory inflation” (37, 38). This 
characteristic of CMV induced CD8+ T cell response could be 
exploited in the development of CD8+ T cell-based live vaccines 
(39–42). Live attenuated vaccines imitate natural infection by 
inducing a broad cellular and humoral response to variety of 
antigens, which makes them superior to subunit vaccines. Still, 
there are concerns about using live virus as a vaccine as it might 
cause unwanted virulence, especially in high-risk individuals 
such as immunocompromised patients. CMV has many nones-
sential genes involved in subversion of immune response and 
the deletion of those genes enables the manipulation of its 
virulence and the quality of immune response. In our previous 
studies we took advantage of virus lacking the NKG2D immu-
noevasin to generate recombinant immunologically attenuated 
vaccine vector RAE-1γMCMV that retained the ability to 
induce a strong adaptive response (21–23). NKG2D ligands are 
differently expressed and regulated in tissues, they differ in the 
affinity for the receptor and certain ligands are restricted to the 
particular mouse strains (11, 43–45). MULT-1 has the highest 
affinity for the receptor among all mouse NKG2D ligands and 
its transcripts were found in most of the healthy tissues, but its 
protein expression was strictly regulated on posttranslational 
FigUre 4 | MULT-1MCMV induces protective anti-viral CD8+ T cell response. (a) C57BL/6 CD45.1+ mice were infected footpad (f.p.) with 2 × 105 PFU of wild-type 
(WT) MCMV, RAE-1γMCMV, and MULT-1MCMV. After 6 weeks 106 CD8+ T cells sorted from spleens were intravenously transferred into NK depleted, irradiated 
C57BL/6 recipients challenged f.p. with 105 PFU of WT MCMV. Eight days after infection organs of recipient animals were collected and viral titer was determined by 
plaque assay (n = 4–8). (B) C57BL/6 mice were infected f.p. with 2 × 105 PFU of WT MCMV, RAE-1γMCMV, and MULT-1MCMV and after 6 weeks 105 CD8+ T cells 
sorted from spleen were transferred into C57BL/6 newborn mice challenged i.p. with 500 PFU of WT MCMV. On day 14 after challenge infection viral titer was 
determined in organs by plaque assay (n = 4–6). Representative data of two independent experiments are shown. Data are presented as medians with interquartile 
range and analyzed using Mann–Whitney U test. Asterisks denote significant values: *P < 0.05; **P < 0.01. Abbreviation: DL, detection limit.
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level (46). To exploit those differences in the context of a MCMV-
based vaccine, we constructed MULT-1MCMV and compared 
it with WT MCMV and RAE-1γMCMV. MULT-1MCMV was 
highly immunologically attenuated, but nevertheless induced 
a strong and protective antigen-specific CD8+ T cell and anti-
body response. Thus, this study further supports the idea that 
attenuated recombinant CMVs expressing NKG2D ligands can 
be used as efficient vaccines and vaccine vectors.
It is well known that NK cell response can also shape the adap-
tive immune response (47). The most extensively studied example 
of strong NK control of MCMV infection is the direct recognition 
of viral protein m157 by the activating NK receptor Ly49H, lead-
ing to efficient virus control (36, 48). In most cases, a strong NK 
control would impair CD8+ T cell responses presumably due to 
the lower viral burden and cytokine milieu diminishing antigen 
presentation (49, 50). Indeed, during MCMV infection the lower 
viral burden reduces the magnitude of long-term CD8+ T cell 
response but does not impact its kinetics (51, 52). Paradoxically, 
it has been shown that blocking viral replication increases 
CD8+ T  cell response to non-inflationary epitopes presented 
by preserved dendritic cells (DCs) which would otherwise be 
depleted due to type I IFNs (53, 54). Interestingly, this effect was 
not evident in the population of inflationary CD8+ T cells. While 
convectional non-inflationary CD8+ T  cells are preferentially 
primed by cross-presented antigens on DCs (55), inflationary 
CD8+ T  cells are originating from cells primed early in infec-
tion as well as from constantly replenished short-lived effectors 
(56) maintained at high levels by sporadic virus reactivations 
in non-hematopoietic cells (30, 57). Differential requirements 
in generation of non-inflationary and inflationary CD8+ T cells 
in MCMV infection might explain these findings (58). Here we 
show that despite efficient NK-mediated virus control, MULT-
1MCMV induces CD8+ T  cell response of similar or greater 
magnitude compared to WT MCMV to both non-inflationary 
and inflationary epitopes. While all viruses induced comparable 
CD8+ T cell response to viral antigens, RAE-1γMCMV induced 
a higher number of SIINFEKL-specific CD8+ T cells. Somewhat 
better response to non-inflationary epitope M45 in mice infected 
with recombinant viruses expressing NKG2D ligands could be 
explained either by a better cross-presentation due to preserved 
DCs in absence of strong infection or immune function of these 
proteins (21, 22, 54). The strong engagement of NKG2D and 
activation of NK cells might result in an environment favoring 
antigen presentation. Alternatively, the co-stimulation signal 
FigUre 5 | Vaccination of female mice with MULT-1MCMV induces MCMV-specific antibodies which protect their offspring from MCMV challenge. (a) BALB/c 
females were immunized intravenously with 2 × 105 PFU of wild-type (WT) MCMV, RAE-1γMCMV, and MULT-1MCMV 2 weeks prior mating. Six hours after birth, 
their offspring were either bled to collect sera or intraperitoneally challenged with 500 PFU of WT MCMV. (B) Titers of MCMV-specific antibodies in sera of 
immunized mothers (in average 1.5 month after infection) and their offspring (6 h after birth) are shown. (c) WT MCMV challenged newborn mice were sacrificed 
9 days after infection and viral titer was determined in their organs by plaque assay. Each circle represents an individual animal. Results are presented as pooled 
data from two independent experiments. Data are presented as mean ± SEM (B) or medians (c) and were analyzed using two-way ANOVA (B) and Mann–Whitney 
U test (c). Asterisks denote significant values: *P < 0.05; **P < 0.01; ***P < 0.001. Abbreviation: DL, detection limit.
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by engagement of NKG2D on CD8+ T cells could rescue T cell 
responses which would otherwise be weaker due to strong viral 
control and action of other viral evasins. The importance of CD8+ 
T cell co-stimulation is evident from the fact that TCR signaling 
without an appropriate co-stimulation signal drives CD8+ T cells 
to the state of anergy rather than activation (59). CMVs have 
developed multiple mechanisms to evade CD8+ T cell recogni-
tion of infected cells. Indeed, MCMV possess several genes 
encoding proteins which interfere with antigen presentation by 
downregulating the expression of MHC I molecules (6). Ligands 
for the major T  cell co-stimulatory receptor CD28 are also 
targeted by viral immunoevasion (59–61). CD28/B7-mediated 
co-stimulation is indispensable in acute infection and for the 
establishment of CD8+ T cell memory in MCMV (62). In LCMV 
infection, the absence of B7-mediated co-stimulation can be 
substituted with other co-stimulatory pathways (63). Though 
this was not shown for CD8+ T cell response in herpes viruses, it 
suggests that under certain conditions co-stimulatory pathways 
might act compensatory to each other. Our in  vitro studies 
showed that RAE-1γMCMV and MULT-1MCMV infected 
BMDCs have an improved capacity to stimulate CD8+ T  cells 
compared to WT MCMV. The engagement of co-stimulatory 
receptor NKG2D on CD8+ T  cells was reported to promote 
proliferation and cytotoxic capacity of antigen-specific CD8+ 
T cells in various experimental settings (64–66), as well as rescue 
memory of unhelped CD8+ T cells (67). Moreover, it was shown 
recently that engagement of NKG2D on NK  cells augments 
their expansion during MCMV infection (68). Therefore, we 
hypothesize that co-stimulatory function of NKG2D on CD8+ 
T cells might overcome multiple ways of viral interference with 
antigen presentation and downregulation of co-stimulatory 
molecules resulting in a better stimulation and improved CD8+ 
T cell responses in vivo.
Apart from prompting durable CD8+ T cell memory, the abil-
ity to induce humoral response is another vital feature of CMV 
vaccine, since antigen-specific antibodies are able to cross the pla-
cental barrier and are the first to protect the fetus and newborns 
against congenital infection (69, 70). Despite the lower antigenic 
load, MULT-1MCMV immunization induced MCMV-specific 
antibodies capable of protecting offspring against a challenge 
infection.
Another interesting finding of this study was the rapid attenu-
ation of MULT-1MCMV pronounced in perinatally infected 
newborns. This is in agreement with our recent study showing 
that MULT-1MCMV failed to reach the brain of mice infected 
as newborns resulting in the absence of brain inflammation 
and establishment of tissue-resident memory CD8+ T  cells 
(71). NK cells are immature in newborns, at least partially due 
to the presence of high levels of immune suppressive TGF-β, 
which makes newborns highly susceptible to viral infections 
(72). Since NKG2D is expressed early in ontogeny of NK cells 
(73), we speculate that the engagement of NKG2D with a high 
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affinity ligand might overcome the suppressive environment in 
newborn mice, but the exact mechanism of MULT-1MCMV 
control in newborns remains elusive. Yet, this study demonstrates 
the feasibility of CMV-based vaccine vectors to be used even in 
newborns.
Altogether, we show for the first time that MCMV express-
ing the high affinity NKG2D ligand MULT-1 has numerous 
favorable features of a vaccine such as being highly attenuated, 
but still able to induce both cellular and humoral adaptive 
immunity. We have established the vaccine properties of 
MULT-1MCMV against MCMV infection, which does not 
exclude the prospect to test its capacity as a vector vaccine. In 
conclusion, by comparing recombinant viruses expressing dif-
ferent NKG2D ligands, we confirmed the dual role of NKG2D 
in mediating a strong virus control, while retaining CD8+ T cell 
response equivalent or better than WT virus infection, which 
can serve as a model approach for the development of a similar 
HCMV-based vaccine vector.
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